May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Pregnane X Receptor Expression in Untreated and Treated Retinoblastoma
Author Affiliations & Notes
  • M. W. Wilson
    Ophthal/Hamilton Eye Int, Univ of Tennessee Health Sci Ctr, Memphis, Tennessee
  • C. H. Fraga
    Pharmaceutical Sciences,
    St Jude Children's Research Hospital, Memphis, Tennessee
  • C. Rodriguez-Galindo
    Solid Tumor,
    St Jude Children's Research Hospital, Memphis, Tennessee
  • N. Hagedorn
    Pharmaceutical Sciences,
    St Jude Children's Research Hospital, Memphis, Tennessee
  • C. F. Stewart
    Pharmaceutical Sciences,
    St Jude Children's Research Hospital, Memphis, Tennessee
  • Footnotes
    Commercial Relationships M.W. Wilson, None; C.H. Fraga, None; C. Rodriguez-Galindo, None; N. Hagedorn, None; C.F. Stewart, None.
  • Footnotes
    Support Research to Prevent Blindness, New York, New York
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1606. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. W. Wilson, C. H. Fraga, C. Rodriguez-Galindo, N. Hagedorn, C. F. Stewart; Pregnane X Receptor Expression in Untreated and Treated Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1606. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

The Pregnane X Receptor (PXR) is an orphan nucleotide receptor that induces the expression of select ATP-binding cassette (ABC)/ multidrug resistance proteins such as multidrug resistance-1/ P-glycoprotein (MDR1/P-gp), multidrug resistant protein 1 (MRP1/ABCC1), multidrug resistant protein 2 (MRP2/ABCC2), multidrug resistant protein 4 (MRP4/ABCC4) and breast cancer resistance protein (BCRP/ABCG2). The purpose of our study is to compare the expression of PXR in retinoblastoma tumors among eyes treated with primary enucleation and eyes treated with primary systemic chemotherapy and/or external beam radiation (EBRT) and to correlate these findings with the expression of the multidrug resistance proteins.

 
Methods:
 

A tissue microarray was constructed with the archival specimens from 50 enucleated eyes. Using standard immunohistochemical techniques, the tissue microarrays were studied for the expression of PXR and 5 ABC transporters: MDR1, MRP1, MRP2, MRP4 and BCRP.

 
Results:
 

Of the 50 eyes studied, 37 were primarily enucleated, 5 had been treated with chemotherapy alone, and 8 had been treated with both chemotherapy and EBRT. Results are summarized for each cohort in the table.  

 
Conclusions:
 

Preliminary analysis of our data shows that the majority of both untreated and treated retinoblastoma tumors express PXR. Untreated eyes expressed PXR at rates similar to treated eyes (65% versus 69%). Given the variable expression of the multidrug resistant proteins in the same retinoblastoma tumors, it does not appear that PXR alone accounts for the induction of any specific or particular ABC transporter.

 
Keywords: retinoblastoma • pathology: human • receptors: pharmacology/physiology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×